Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Deferred Revenue (2024 - 2025)

Prime Medicine filings provide 2 years of Current Deferred Revenue readings, the most recent being $7.8 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 10.32% to $7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.8 million, a 10.32% increase, with the full-year FY2025 number at $7.8 million, up 10.32% from a year prior.
  • Current Deferred Revenue hit $7.8 million in Q4 2025 for Prime Medicine, up from $7.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $9.3 million in Q3 2024 to a low of $7.0 million in Q3 2025.